Teriparatide, the anabolic agent, has received a boost in status as a preferentially effective treatment for glucocorticoid-induced osteoporosis in the form of a second, confirmatory, randomized double-blind trial.
The trial demonstrated that the drug achieves substantially greater increases in bone mineral density compared to a bisphosphonate.
These positive study findings are bolstered by a biologically plausible mechanism of benefit, according to the observations of Dr. Kenneth G. Saag at the annual meeting of the American Society for Bone and Mineral Research.
A recent study has determined that glucocorticoid-induced osteoporosis (OP) is now treatable with a synthetic form of the human parathyroid hormone, Teriparatide.
It was found by the researchers that patients with glucocorticoid-induced OP and administered with teriparatide for 36 months had a greater increase in bone mineral density (BMD) and fewer new vertebral fractures than those treated with alendronate.
The findings of this study are published in the November issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR).
Forteo or injectable Teriparatide is superior to Fosamax or oral Alendronate, in a head-to-head comparison, for increasing the level of bone mineral density (BMD) by as much as two times, according to investigators.
It was remarked by Philip N. Sambrook, M.D., of the University of Sydney that teriparatide could be considered as a first-line therapy for treating osteoporosis induced by steroids.
Kenneth Saag, M.D., of the University of Alabama at Birmingham and his colleagues said that considerable BMD improvements in the spine and hip regions are possible with Teriparatide.
A recent study has determined that Teriparatide, a synthetic form of the human parathyroid hormone, could be used to effectively treat steroid-induced osteoporosis.
It was found by the involved researchers that osteoporosis patients when treated with teriparatide for a period of 36 months had a greater increase in BMD (bone mineral density) and fewer new vertebral fractures than those treated with alendronate.
The findings of this study were published in an issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology(ACR).
Parathyroid hormone (PTH), known as teriparatide in drug form, is the first ever drug that was recently found effective in preventing cartilage loss from osteoarthritis following injury to a joint. It was also found that the hormone can even regenerate some cartilage lost because of osteoarthritis.
This finding was disclosed at an early study presented September 12 at the annual meeting of the American Society for Bone and Mineral Research in Denver.
The study along with Randy Rosier, M.D., Ph.D., professor within the Department of Orthopaedics and Rehabilitation at the University of Rochester Medical Center was led by Erik Sampson, Todd O’Brien, Di Chen, Susan Bukata, J. Edward Puzas, Regis O’Keefe and Michael Zuscik within the Department of Orthopaedics and by Hani Awad in the Department of Biomedical Engineering at the University of Rochester Medical Center.
The injectable form of Teriparatide, Forteo, is superior to oral Alendronate, Fosamax, in a head-to-head comparison when it comes to improving bone mineral density (BMD) by as much as twice.
Teriparatide promotes greater increases in bone-mineral density at the spine and hip, as per Kenneth Saag, M.D., of the University of Alabama at Birmingham and his colleagues.
Philip N. Sambrook, M.D., of the University of Sydney, said that Saag’s findings suggest that teriparatide is a superior drug for treating steroid-induced Osteoporosis.
Glucocorticoid-induced osteoporosis (OP) is better treated with a synthetic form of the human parathyroid hormone, Teriparatide. This finding was disclosed by a recent study. The study findings were published in the November 2009 issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR).
It was disclosed by the researchers that patients with OP and treated with Teriparatide for a period of 36 months experienced greater increase in bone mineral density (BMD) and fewer new vertebral fractures than those treated with alendronate.
The measures of this research included changes in lumbar spine and hip bone, BMD, changes in bone biomarkers, fracture incidence, and safety. The 36-month, randomized, double-blind, controlled trial, led by Kenneth Saag, M.D., from the University of Alabama, was conducted at 76 centers located in 13 countries.
Glucocorticoid-induced osteoporosis (OP) is now treatable with Teriparatide, which is a synthetic form of the human parathyroid hormone, according to a recent study.
It was found by the researchers that patients with glucocorticoid-induced osteoporosis and treated with teriparatide for a period of 36 months had a significant increase in BMD (bone mineral density) and fewer new vertebral fractures than those treated with alendronate.
The findings of this study were published in the November issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR).
Parathyroid hormone (PTH), known as teriparatide in drug form, has been found useful in preventing loss of cartilage resulting from osteoarthritis following injury to a joint. It is also found to regenerate a part of cartilage lost due to osteoarthritis.
These findings were revealed by an early study presented September 12 at the annual meeting of the American Society for Bone and Mineral Research in Denver.
It is worth noting here that the presently followed drugs like steroids or non-steroidal anti-inflammatory agents (e.g. Advil, Aleve) can reduce pain but are unable to address cartilage loss due to osteoarthritis, which is believed to affect more than 50 million Americans by 2020.
The study was co-led by Erik Sampson, Todd O’Brien, Di Chen, Susan Bukata, J. Edward Puzas, Regis O’Keefe and Michael Zuscik within the Department of Orthopaedics and by Hani Awad in the Department of Biomedical Engineering at the University of Rochester Medical Center, and funded by the National Institutes of Health.
According to findings of a recent study that was published in the November issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR), glucocorticoid-induced osteoporosis (OP) is easily treatable with Teriparatide, a synthetic form of the human parathyroid hormone.
Glucocorticoids aresteroid hormones, which are produced naturally in the body and can be termed as synthetically created compounds meant for the purpose of reducing inflammation. These steroid drugs are used for controlling inflammation in patients suffering with ailments such as rheumatoid arthritis, systemic lupuserythematosus, asthma, and Crohn’s disease.
Kenneth Saag, M.D., from the University of Alabama, led this 36-month, randomized, double-blind, controlled trial, and recommended that teriparatide is an effective treatment option for patients with steroid-induced OA.
Teriparatide Becomes Preferred Drug for Steroid-Induced Osteoporosis
Teriparatide, the anabolic agent, has received a boost in status as a preferentially effective treatment for glucocorticoid-induced osteoporosis in the form of a second, confirmatory, randomized double-blind trial.
A recent study has determined that glucocorticoid-induced osteoporosis (OP) is now treatable with a synthetic form of the human parathyroid hormone, Teriparatide.
Forteo or injectable Teriparatide is superior to Fosamax or oral Alendronate, in a head-to-head comparison, for increasing the level of bone mineral density (BMD) by as much as two times, according to investigators.
A recent study has determined that Teriparatide, a synthetic form of the human parathyroid hormone, could be used to effectively treat steroid-induced osteoporosis.
Parathyroid hormone (PTH), known as teriparatide in drug form, is the first ever drug that was recently found effective in preventing cartilage loss from osteoarthritis following injury to a joint. It was also found that the hormone can even regenerate some cartilage lost because of 
Glucocorticoid-induced osteoporosis (OP) is better treated with a synthetic form of the human parathyroid hormone, Teriparatide. This finding was disclosed by a recent study. The study findings were published in the November 2009 issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR).
Glucocorticoid-induced osteoporosis (OP) is now treatable with Teriparatide, which is a synthetic form of the human parathyroid hormone, according to a recent study.
Parathyroid hormone (PTH), known as teriparatide in drug form, has been found useful in preventing loss of cartilage resulting from osteoarthritis following injury to a joint. It is also found to regenerate a part of cartilage lost due to osteoarthritis.
According to findings of a recent study that was published in the November issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR), glucocorticoid-induced osteoporosis (OP) is easily treatable with Teriparatide, a synthetic form of the human parathyroid hormone.